NCT00671372已完成1 期
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Dulanermin Administered Intravenously in Combination With Camptosar®/Erbitux® Chemotherapy or the Folfiri Regimen With or Without Bevacizumab in Subjects With Previously Treated Metastatic Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 主要终点
- The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab)
研究概览
简要总结
This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab (only for Cohort 6 subjects who have not received prior bevacizumab therapy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Age >= 18 years
- •Histologically confirmed CRC with evidence of metastases and measurable tumor lesion(s)
- •Progression of disease following, or intolerance to, treatment with 5-fluorouracil-based therapy
- •Progression of disease during or within =< 6 months following the last dose of a prior first-line treatment with a fluoropyrimidine and oxaliplatin-based chemotherapy plus bevacizumab for metastatic disease
- •Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential (use per institutional standard)
- •Life expectancy of > 3 months
- •Willingness and capability to be accessible for study follow-up
排除标准
- •Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response
- •Radiation therapy to a peripheral lesion within 14 days prior to Day 1; Radiation therapy to a thoracic, abdominal or pelvic field within 28 days prior to Day 1
- •Chemotherapy, hormonal therapy, or immunology within 4 weeks prior to Day 1
- •Previous exposure to DR4-targeted therapy or DR5-targeted therapy
- •Evidence of clinically detectable ascites on Day
- •Other invasive malignancies within 5 years prior to Day 1 (other than basal cell carcinoma of the skin or in situ carcinoma of the cervix)
- •History or evidence upon physical examination of CNS disease
- •Active infection requiring parenteral antibiotics on Day 1
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study and fine needle aspirations within 7 days prior to Day 1
- •Pregnancy or lactation
- •Serious nonhealing wound, ulcer, or bone fracture
- •Current or recent participation in another experimental drug study
- •Clinically significant cardiovascular disease
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications
- •Cohort 5 only: Subjects who have a Kras mutation will be excluded from enrollment
- •The following exclusion criteria apply only to subjects who have received prior bevacizumab and are enrolled in Cohort 6: four or more prior doses of bevacizumab therapy, inadequately controlled hypertension, history of hypertensive crisis or hypertensive encephalopathy, history of arterial thromboembolic event 6 months prior to Day 1, proteinuria, history of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
研究组 & 干预措施
Cohorts 1-5
Experimental
干预措施: cetuximab (Drug)
Cohorts 1-5
Experimental
干预措施: dulanermin (Drug)
Cohorts 1-5
Experimental
干预措施: irinotecan (Drug)
Cohorts 6, 6A, 7, 7A
Experimental
干预措施: FOLFIRI regimen (Drug)
Cohorts 6, 6A, 7, 7A
Experimental
干预措施: bevacizumab (Drug)
Cohorts 6, 6A, 7, 7A
Experimental
干预措施: dulanermin (Drug)
结局指标
主要结局
The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab)
时间窗: Length of study
The safety and tolerability of dulanermin administered in combination with Camptosar and Erbitux
时间窗: Length of study
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT02519452Janssen Research & Development, LLC120
已完成
2 期
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AMLAcute Myeloid LeukemiaNCT03280030Novartis Pharmaceuticals67
已完成
1 期
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)Renal ImpairmentMultiple MyelomaNCT01575925Celgene25
已完成
1 期
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple MyelomaMultiple MyelomaNCT01615029Janssen Research & Development, LLC45
进行中（未招募）
2 期
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLFLT3-mutated Acute Myeloid LeukemiaNCT03591510Novartis Pharmaceuticals22